Get the Stockscreener App
258.28
0.35%
0.89
After Hours:
256.36
-1.92
-0.74%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $258.28, with a volume of 1.23M.
It is up +0.35% in the last 24 hours and up +2.73% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$257.39
Open:
$255.92
24h Volume:
1.23M
Relative Volume:
1.20
Market Cap:
$37.63B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
25.53
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
+2.64%
1M Performance:
+2.73%
6M Performance:
-4.06%
1Y Performance:
+10.80%
1-Day Range:
$254.05
$260.00
1-Week Range:
$250.19
$260.00
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
258.28 | 37.50B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
497.42 | 176.23B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
174.21 | 50.22B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.08 | 41.28B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.39 | 37.20B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Mitsubishi UFJ Asset Management Increases ResMed Stake - National Today
People say sleep matters most for health, yet quality rest is rare - Stock Titan
Andra AP fonden Cuts Stake in ResMed Inc. - National Today
RMD (NYSE: RMD) broker files Rule 144 notice for 1,000 shares - Stock Titan
Sleep apnea specialist Resmed announces plans for major new distribution centre - Mugglehead Investment Magazine
ResMed Inc. (RMD) Stock Analysis: Exploring a 16% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Andra AP fonden Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc.: The Sleep-Tech Stock You Should Not Ignore in 2026 - AD HOC NEWS
RMD PE Ratio & Valuation, Is RMD Overvalued - Intellectia AI
RMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ResMed Greenwood Hub Aims To Tighten Supply Chain And Patient Access - Sahm
Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
Intech Investment Management LLC Has $8.57 Million Holdings in ResMed Inc. $RMD - MarketBeat
Sleep Tech Demand Fuels ResMed - AlphaStreet News
ResMed Expands Greenwood Hub As Investors Weigh Valuation And Soft Momentum - Yahoo Finance
ResMed Inc (NYSE:RMD): A Durable Dividend Stock Built on Financial Strength - ChartMill
The Bull Case For ResMed (RMD) Could Change Following New Greenwood Distribution Hub Plan – Learn Why - simplywall.st
Dakota Wealth Management Grows Stake in ResMed Inc. $RMD - MarketBeat
Is ResMed Stock A Trap Or A Missed Opportunity? - Trefis
Why I would buy ResMed and these quality blue chips now - The Motley Fool Australia
Is ResMed Stock Poised for a Rally? - Trefis
Shares of Resmed Fall 3% After Declaring Plan to Open New US Distribution Center - marketscreener.com
Resmed to open new distribution center in Indiana - MassDevice
ResMed Greenwood Hub Aims To Tighten Logistics And Support Growth - simplywall.st
Braun: Resmed to build $30 million facility in Greenwood - Fox 59
ResMed Inc (RMD) Shares Gap Down to $251.69 on Feb 24 - GuruFocus
ResMed opens new distribution center in Greenwood, Indiana - TipRanks
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana - marketscreener.com
Resmed (RMD) Expands U.S. Footprint with New Indiana Distributio - GuruFocus
ResMed to Open New Distribution Center in Indiana - marketscreener.com
ResMed expands US operations with new distribution center in Indiana - marketscreener.com
New Resmed hub brings 100+ jobs, speeds essential healthcare deliveries - Stock Titan
LGT Capital Partners LTD. Decreases Stock Position in ResMed Inc. $RMD - MarketBeat
Anti-snoring Devices Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenue Insights - GlobeNewswire Inc.
Dana Investment Advisors Inc. Sells 4,272 Shares of ResMed Inc. $RMD - MarketBeat
Washington Trust Advisors Inc. Lowers Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Emerges as a Prime Quality Investing Candidate - ChartMill
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Sells 18,989 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Resmed Founder to Receive Prestigious Award - Sleep Review
NEOS Investment Management LLC Has $3.71 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
ResMed Narrowing Search for U.S. Device Manufacturing Site -- Interview - 富途牛牛
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Sleep Aids: Trends, Technologies and Global Markets to 2030 Featuring Key Players Fisher & Paykel Healthcare, ResMed, Philips, Alphabet, Apple and More - Yahoo Finance UK
A Look At ResMed (RMD) Valuation After Robust Q2 Beat And Upgraded Analyst Outlook - Sahm
Stock Recap: Is ResMed Inc stock showing strong momentumEarnings Recap Report & High Yield Equity Trading Tips - baoquankhu1.vn
ResMed Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com
Skandinaviska Enskilda Banken AB publ Has $23.55 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Vanguard Group Inc. Acquires 293,515 Shares of ResMed Inc. $RMD - MarketBeat
W.G. Shaheen & Associates DBA Whitney & Co Sells 4,003 Shares of ResMed Inc. $RMD - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):